Patents by Inventor Boris Engels

Boris Engels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of making chimeric antigen receptor-expressing cells
    Patent number: 12630604
    Abstract: The present disclosure pertains to methods of making immune effector cells (for example, T cells or NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods. Also disclosed herein are methods of using such compositions for treating a disease, for example, cancer, in a subject.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: May 19, 2026
    Assignee: Novartis AG
    Inventors: Louise Mary Treanor, Michael R. Greene, Jennifer Brogdon, Boris Engels, Glenn Dranoff, Olja Kodrasi, Hyungwook Lim, Akash Sohoni, Elizabeth Dorothy Pratico, Anniesha Hack, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, John Blankenship, Brian Holmberg, Chonghui Zhang, Dexiu Bu, Andrew Patrick Price, Xu Zhu, Andrew Marc Stein, Attilio Bondanza
  • Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer
    Patent number: 12594321
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: December 5, 2023
    Date of Patent: April 7, 2026
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Ming Lei, Jimin Zhang
  • CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20260042812
    Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
    Type: Application
    Filed: May 22, 2025
    Publication date: February 12, 2026
    Inventors: Boris Engels, Carla Patricia Guimaraes
  • CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20260034195
    Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.
    Type: Application
    Filed: July 8, 2025
    Publication date: February 5, 2026
    Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louis Treanor, Chonghui Zhang, Xu Zhu
  • MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
    Publication number: 20250319179
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: January 6, 2025
    Publication date: October 16, 2025
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • Chimeric antigen receptors and uses thereof
    Patent number: 12383601
    Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: August 12, 2025
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
  • CD19 and CD22 chimeric antigen receptors and uses thereof
    Patent number: 12344651
    Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
    Type: Grant
    Filed: March 27, 2024
    Date of Patent: July 1, 2025
    Assignee: Novartis AG
    Inventors: Boris Engels, Carla Patricia Guimaraes
  • HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20250011461
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Application
    Filed: August 2, 2024
    Publication date: January 9, 2025
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
    Patent number: 12186278
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: January 7, 2025
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, Dana Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20240390492
    Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
    Type: Application
    Filed: March 27, 2024
    Publication date: November 28, 2024
    Inventors: Boris Engels, Carla Patricia Guimaraes
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20240317850
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: April 2, 2024
    Publication date: September 26, 2024
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20240294662
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Application
    Filed: April 26, 2024
    Publication date: September 5, 2024
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20240252538
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Application
    Filed: December 5, 2023
    Publication date: August 1, 2024
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • Human mesothelin chimeric antigen receptors and uses thereof
    Patent number: 11999794
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: June 4, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 11981731
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: May 14, 2024
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • CD19 and CD22 chimeric antigen receptors and uses thereof
    Patent number: 11975026
    Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 7, 2024
    Assignee: Novartis AG
    Inventors: Boris Engels, Carla Patricia Guimaraes
  • Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
    Patent number: 11872249
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 16, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20230256017
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 17, 2023
    Inventors: Jennifer BROGDON, Glenn DRANOFF, Michael R. GREENE, Anniesha HACK, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Amy RAYO, Jennifer YANG, Brian Walter GRANDA, Attilio BONDANZA, Boris ENGELS, Hyungwook LIM, Akash SOHONI, Louise TREANOR, Xu ZHU, Carla GUIMARAES, Shyamali JAYASHANKAR, Sandeep Tharian KOSHY, Regis CEBE, Michael BARDROFF, Sandra MILLER
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20230174933
    Abstract: This disclosure provides methods of making immune effector cells (for example, T cells, NK cells) that comprise (i) a nucleic acid molecule that encodes a controllable chimeric antigen receptor (CCAR) or (ii) a nucleic acid molecule that encodes a CAR and a regulatory molecule, and compositions generated by such methods.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 8, 2023
    Inventors: Jennifer BROGDON, Seth CARBONNEAU, Glenn DRANOFF, Michael R. Greene, Anniesha HACK, Marc Horst Peter HILD, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Attilio BONDANZA, Boris ENGELS, Carla Patricia Pinto GUIMARAES, Hyungwook LIM, Sujata SHARMA, Akash SOHONI, Louise TREANOR, Xu ZHU
  • Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
    Patent number: RE49847
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: February 27, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young